ATsens

Seongnam-Si, Gyeonggi-Do, South Korea All South Korea companies → — Founded 2017

Medical Device / Hardware Specialty-Focused AI Wearables / RPM

Cardiology Family Medicine Internal Medicine

Cardiology AI Wearables & Remote Monitoring (RPM)

Private Equity-Backed — $8.76M

Claim this company

Products

AT-Patch (ATP-C130/ATP-C70)

ATsens Co.

Cardiology AI

AT-Patch by ATsens Co. is an FDA-cleared wearable ECG monitor offering up to 14 days of continuous cardiac monitoring with high accuracy, a shower-proof design, and integrated AI-powered analysis software for enhanced arrhythmia detection.

N/a

See all 1 product →

About ATsens

ATsens is a South Korean healthcare platform company specializing in vital signal medical technology, with a core focus on AI-powered solutions for cardiac monitoring. Their flagship offering, the AT-Heart solution, comprises the AT-Patch, a small, lightweight, and low-powered patch-type electrocardiograph (ECG) designed for uninterrupted, long-term continuous cardiac monitoring, often for up to 14 days. This device is complemented by the AT-Note smartphone application for live ECG viewing and symptom recording, and the AT-Report, an advanced software that utilizes AI algorithms for sophisticated and accurate ECG data analysis and reporting.

The company’s technology aims to enhance diagnostic capabilities for healthcare professionals, particularly in detecting intermittent arrhythmias that might be missed by conventional short-term tests. By providing comprehensive, physician-reviewed diagnostic reports with rapid turnaround times, ATsens seeks to improve workflow efficiency, increase arrhythmia diagnosis rates, and potentially reduce healthcare costs associated with repeated testing. ATsens is also actively expanding its product pipeline to develop and commercialize other wearable digital healthcare devices and services, including continuous glucose monitors (CGM), continuous blood pressure (CBP) devices, and sleep apnea meters, with a vision to build a holistic healthcare platform for disease prediction and preventive treatment.

Focus Areas

Wearable ECG monitoring arrhythmia detection AI analysis long-term cardiac monitoring healthcare platform bio-signal based medical technology

Business Intelligence

Key Investors	DreamStone Private Equity, DAYLI Partners, Gravity Ventures (Korea), Hana Financial Group, Intops Investment, DS Asset
Partnerships	U.S. distributor (unnamed), EnaMed (Greece), Hanmi Pharmaceutical Co., Ltd. (Korea), Chungnam National University Sejong Hospital and Sejong-si, Polish state hospital, over 10 tertiary and general hospitals and national university hospitals in Korea, GS Global (for North American market entry)
Technology	Bio-signal based healthcare platform, ECG sensing, data processing algorithm, AI analysis algorithm, cloud and telemetry, information security, AT-Heart Platform
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

Wearable ECG Monitoring

ATsens' AT-Patch is a small (13g), lightweight, and comfortable single-lead ECG monitor designed for ambulatory use. It is shower-proof (IP44/IP57) and allows patients to maintain normal daily activities. The device offers up to 14 days of continuous monitoring without the need for charging or electrode replacement, powered by a single-use coin cell battery.

Arrhythmia Detection

The AT-Patch features advanced technology, including a proprietary sensor chip and short-length electrodes, to enhance high-accuracy ECG signal detection and significantly reduce noise from body movement. This design aims to effectively capture intermittent arrhythmias often missed by shorter-term monitoring methods. The AT-Report software can classify 17 types of arrhythmia.

AI Analysis

The AT-Report ECG Analysis Software utilizes proprietary algorithms for sophisticated and accurate ECG analysis. This automated analysis is combined with physician over-read by board-certified cardiologists to produce comprehensive and clinically actionable diagnostic reports.

Long-term Cardiac Monitoring

The AT-Patch enables uninterrupted long-term cardiac monitoring for up to 14 days, which is crucial for detecting elusive arrhythmias. Its high power efficiency ensures continuous operation throughout the monitoring period.

Healthcare Platform

ATsens offers the 'AT-Heart' total ECG monitoring solution, comprising the AT-Patch wearable monitor, the AT-Note smartphone app for live ECG viewing and symptom recording, and the AT-Report analysis software. Additionally, the AT-Monitoring system provides real-time ECG monitoring for hospitalized patients with arrhythmia alarm functionality.

Bio-signal Based Medical Technology

ATsens leverages advanced bio-signal technology with multiple ECG-related patents covering signal sensing, device design, and ECG signal processing algorithms. Their proprietary sensor chip and short-length electrode are engineered for high-performance ECG signal acquisition and effective noise reduction.

Physician Tip

For physicians, ATsens stands out due to its **clinically actionable diagnostic reports** that combine advanced AI analysis with crucial **board-certified cardiologist over-read and dual review**, ensuring high accuracy and reliability. The **rapid 48-hour report turnaround** significantly streamlines workflow and supports faster clinical decision-making. The **long-term (up to 14-day) continuous monitoring** capability, coupled with the **patient-friendly, shower-proof AT-Patch**, leads to improved patient compliance and a higher diagnostic yield for intermittent arrhythmias. Furthermore, the **AT-Monitoring system offers real-time insights for inpatients**, enhancing patient safety and hospital efficiency. The ability to receive **customized reports** tailored to practice needs and the backing of **multiple international regulatory clearances (FDA, CE, PMDA, MFDS)** provide additional confidence and flexibility.

The ATsens ecosystem integrates the AT-Patch wearable device with the AT-Note smartphone app (Android/iOS) via Bluetooth for live ECG viewing and symptom recording. The AT-Report software processes the collected data using proprietary algorithms, generating comprehensive reports that can be customized and saved in PDF format. The AT-Monitoring system provides real-time data transmission for inpatient settings.

At a glance

Founded 2017

HQ Seongnam-Si, Gyeonggi-Do, South Korea · South Korea

Team size 55

CEO Jeong, Jongook

Funding Private Equity-Backed — $8.76M

FDA clearances 2 (estimated)

Products 1

Products by ATsens

1 product in the directory

AT-Patch (ATP-C130/ATP-C70)

ATsens Co.

Cardiology AI

N/a

What the Web Says

ATsens, a company specializing in healthcare technology, particularly ECG devices, receives mixed reviews. While their products are often praised for accuracy and ease of use by healthcare professionals, employer reviews on platforms like Glassdoor indicate some internal challenges regarding management and work-life balance.

Overall: Mixed

Strengths

Accurate and reliable ECG devices (e.g., ATsens ePatch)
Easy to use and apply for patients and clinicians
Good customer support reported by some users
Innovative technology in cardiac monitoring
Devices are lightweight and comfortable for patients
Effective for long-term ECG monitoring

Limitations

Concerns about management style and communication within the company
Potential for long working hours and work-life balance issues for employees
Some reports of high employee turnover
Limited information available on specific pricing or widespread product comparisons on review sites
Specific product cons are not widely detailed on public review platforms like G2 or Capterra
Lack of detailed employer reviews on some platforms

Based on reviews from: G2, Glassdoor, Capterra, Healthcare IT News/Review Sites (general), Reddit (limited mentions)

Last updated: 2026-07-17

Videos

News, demos, and interviews about ATsens.

Loading videos...

Videos load interactively. If none appear, search YouTube for ATsens →

View all on YouTube

Press & Coverage

KBR

ATsens secures US supply deal for wearable ECG device AT-Patch

ATsens has signed a three-year supply agreement with a major U.S. distributor for its wearable ECG monitoring device AT-Patch and analysis software AT-Report, marking its first large-scale entry into the U.S. market. The deal is valued at approximately $7.2 million for 100,000 units in 2026, expanding to $50 billion (450,000 units) over three years.

2025-07

KBR

ATsens secures coverage for real-time monitoring system for hospitalized patients

ATsens' AT-Monitoring system, a real-time inpatient tracking device, has qualified for insurance benefits in Korea, allowing for continuous ECG and fall monitoring. The company aims to contract with major medical institutions for 4,000 beds by the end of 2025 and expand to 25,000 beds by 2026.

2025-11

KBR

ATsens tops 53,000 cumulative exports of wearable ECG monitor to Japan

ATsens' wearable ECG monitoring device, AT-Patch, has surpassed 53,000 cumulative exports to Japan, five years after entering the market. This achievement highlights the device's consistent utilization in Japan's highly regulated medical device market.

2026-05

KBR

ATsens gets $7-million funding for wearable electrocardiogram

ATsens secured $7 million in bridge investment from local investors for its continuous electrocardiogram (ECG) product, AT-Patch (ATP-C120). The funding was driven by market expectations for the launch of Korea's first long-term continuous cardiac monitor.

2021-01

KBR

ATsens's Himalayan arrhythmia risk study using AT-Patch published in JAMA Cardiology

ATsens' study on arrhythmia risk using its AT-Patch device in the Himalayas was published in JAMA Cardiology. This highlights the clinical validation and academic recognition of their wearable ECG technology.

Korea Biomedical Review (via ATsens website)

Korea's 1st long-term continuous ECG device gets FDA approval

ATsens' long-term continuous ECG device received FDA approval, marking a significant regulatory milestone for the company and its entry into the US market.

2022-10

ATsens

AT-Patch, AT-Note and AT-Report are CE MDD certified in Europe

ATsens announced that its AT-Patch, AT-Note, and AT-Report products have received CE MDD certification in Europe. This certification allows ATsens to market and sell its ECG monitoring solutions within the European Union.

2020-05

JMIR Publications

Diagnostic Value of a Wearable Continuous Electrocardiogram Monitoring Device (AT-Patch) for New-Onset Atrial Fibrillation in High-Risk Patients: Prospective Cohort Study

This prospective cohort study investigated the diagnostic value of ATsens' wearable continuous ECG monitoring device (AT-Patch) for new-onset atrial fibrillation in high-risk patients. The research contributes to the understanding of the device's effectiveness in clinical settings.

2023-09

Frequently Asked Questions

What are ATsens' primary wearable ECG monitoring products and their key features for long-term cardiac monitoring?

ATsens' main product is the AT-Patch, a small, lightweight (13g), and shower-proof wearable ECG monitor designed for long-term continuous cardiac monitoring for up to 14 days with a single-use battery. It integrates with the AT-Note smartphone app for live ECG viewing and symptom recording, and the AT-Report software for detailed analysis.

How does ATsens' technology, particularly its AI analysis, contribute to accurate arrhythmia detection?

ATsens utilizes its proprietary AT-Report software, which incorporates advanced AI algorithms for sophisticated ECG analysis. This software can elaborately classify ECG patterns and provides quick data analysis for 17 types of arrhythmia, aiding medical professionals in making accurate diagnoses.

What regulatory compliance and certifications do ATsens' wearable ECG devices and analysis software hold?

ATsens' AT-Patch and AT-Report software have secured U.S. FDA clearance, alongside CE certification for Europe, PMDA approval in Japan, and MHRA certification in the U.K. These certifications enable their products to be marketed and used in numerous international healthcare systems.

Can ATsens' solutions be integrated into existing healthcare platforms, and what kind of support is offered to physicians and administrators?

ATsens aims to provide an innovative healthcare platform, with its AT-Heart solution evolving into a comprehensive 'Heartcare' platform. For support, ATsens Cardiology, an independent diagnostic testing facility (IDTF) partner in the U.S., offers dedicated support, including rapid 48-hour report turnaround and customized reporting, with direct access to their team.

What is ATsens' business model regarding pricing and partnerships for healthcare providers and administrators?

While specific pricing details are not publicly disclosed, ATsens has secured significant supply agreements with U.S. distributors and has contracts in over 30 countries. Their AT-Monitoring system in Korea has qualified for insurance benefits, and they aim for reasonable initial setup costs for hospitals, suggesting a focus on accessible and integrated solutions.

What is the company's stability and future outlook, given its focus on bio-signal based medical technology?

Established in 2017, ATsens has demonstrated stability through significant funding, including $8.76 million raised, and rapid global expansion with product supply contracts in numerous countries. The company holds 35 patents related to ECG sensing, data processing, and AI analysis, indicating a strong foundation and commitment to advancing bio-signal based medical technology.

Related Companies

Suggest an Edit →